These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38781935)

  • 1. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
    Yang P; He S; Ye L; Weng H
    Int Arch Allergy Immunol; 2024; 185(9):910-920. PubMed ID: 38781935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1/UBE2T Inhibits CD8
    Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
    Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
    Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway.
    Jin G; Ma M; Yang C; Zhen L; Feng M
    Thorac Cancer; 2023 Aug; 14(24):2493-2503. PubMed ID: 37423604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
    Zhu J; Li Y; Lv X
    Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer.
    Sun S; Zhou W; Li X; Peng F; Yan M; Zhan Y; An F; Li X; Liu Y; Liu Q; Piao H
    Cancer Commun (Lond); 2021 Sep; 41(9):851-866. PubMed ID: 34251762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.
    Jing H; Meng M; Ye M; Liu S; Cao X; Li K; Liu Y; Zhang J; Wu Y
    J Investig Med; 2024 Jan; 72(1):57-66. PubMed ID: 37804164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETV4 promotes proliferation and invasion of lung adenocarcinoma by transcriptionally upregulating MSI2.
    Cheng T; Zhang Z; Cheng Y; Zhang J; Tang J; Tan Z; Liang Z; Chen T; Liu Z; Li J; Zhao J; Zhou R
    Biochem Biophys Res Commun; 2019 Aug; 516(1):278-284. PubMed ID: 31253395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLA2G2D promotes immune escape in non-small cell lung cancer by regulating T cell immune function through PD-L1-expressing extracellular vesicles.
    Jing H; Cao X; Li K; Liu Y; Meng M; Liu S; Ye M; Zhang J; Wu Y
    Scand J Immunol; 2024 Sep; 100(3):e13393. PubMed ID: 38922971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
    Huang J; Weng Q; Shi Y; Mao W; Zhao Z; Wu R; Ren J; Fang S; Lu C; Du Y; Ji J
    FEBS Open Bio; 2020 Jun; 10(6):1065-1071. PubMed ID: 32237066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
    Zhou F; Wang X; Liu F; Meng Q; Yu Y
    Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
    Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
    Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression.
    Li B; Wang B
    Immunol Invest; 2022 Oct; 51(7):1921-1937. PubMed ID: 35852892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
    Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8 + T Cells in Lung Adenocarcinoma.
    Chen Z; Wang Y; Tang W; Xu S; Yu H; Chen Z
    J Immunother; 2024 Oct; 47(8):313-322. PubMed ID: 39005046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.